Hexarelin
Hexarelin
The most potent growth hormone releasing peptide available, with unique cardioprotective properties from dedicated receptors in heart tissue.
Hexarelin is a synthetic growth hormone releasing peptide and one of the most potent compounds in the GHRP family. It stimulates your pituitary gland to release growth hormone by binding to ghrelin receptors, but on a dose-for-dose basis, it produces stronger growth hormone spikes than any other GHRP including GHRP-2, GHRP-6, and Ipamorelin. A single 100 mcg injection can elevate growth hormone to levels comparable to much higher doses of other peptides.
The peptide is a hexapeptide containing six amino acids with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It was developed as a more potent alternative to GHRP-6. Unlike Ipamorelin, Hexarelin does affect cortisol and prolactin levels, which means it has more potential side effects. However, it compensates for this with unmatched potency and a unique property that no other GHRP shares.
What makes Hexarelin truly unique is its cardiac effects. Research has identified that Hexarelin binds to a separate class of receptors in heart tissue that appear to be different from the ghrelin receptors found in the pituitary. These binding sites have been found throughout the cardiovascular system, with the highest concentrations in the heart ventricles. Studies on isolated hearts showed that Hexarelin improved cardiac function and protected against damage from reduced blood flow, even in animals that lacked normal growth hormone signaling. This suggests the cardiovascular benefits are independent of growth hormone release. Hexarelin is not FDA approved for any medical use.
How It Works
Hexarelin works through the ghrelin receptor pathway similar to other growth hormone releasing peptides, but it has additional mechanisms that set it apart. When you inject Hexarelin, it binds to ghrelin receptors (GHS-R1a) in the hypothalamus and pituitary gland. This binding triggers a cascade inside the cell where the receptor activates adenylyl cyclase, which increases cyclic AMP levels. This leads to calcium-dependent release of growth hormone from somatotroph cells in the pituitary. Additionally, Hexarelin suppresses somatostatin, the hormone that normally puts the brakes on growth hormone release. This dual action of stimulating release while blocking inhibition is why Hexarelin produces such powerful growth hormone pulses.
Hexarelin creates rapid, powerful spikes in growth hormone. Studies show that a single 100 mcg injection can produce growth hormone elevation comparable to injecting 10 IU of synthetic HGH. The critical difference is duration. With Hexarelin, levels return to baseline within 90 minutes to 2 hours. With synthetic HGH, levels stay elevated for 7 to 8 hours. This short duration means Hexarelin needs to be dosed two to three times daily for sustained effects, and the half-life is approximately 30 to 45 minutes.
Research has identified a separate receptor for Hexarelin in heart tissue. Using radioactively labeled Hexarelin, scientists found binding sites throughout the cardiovascular system with the highest levels in the ventricles, followed by the atria, aorta, coronary arteries, and carotid arteries. In isolated heart studies, Hexarelin improved cardiac function and protected against damage from reduced blood flow. These effects occurred even in animals that lacked normal growth hormone signaling, confirming the cardiac benefits are independent of growth hormone release. The growth hormone released by Hexarelin also stimulates IGF-1 production in the liver, driving muscle protein synthesis, fat metabolism, and tissue repair.
Potential Benefits
Most Potent Growth Hormone Release
Hexarelin produces stronger growth hormone spikes than any other GHRP including GHRP-2, GHRP-6, and Ipamorelin. On a microgram-for-microgram basis, it is the most effective growth hormone releasing peptide available. A single 100 mcg injection can elevate growth hormone to levels comparable with much higher doses of other peptides in the same class.
Cardiovascular Protection
Hexarelin has demonstrated cardioprotective effects in research studies through dedicated cardiac receptors that are distinct from pituitary ghrelin receptors. It appears to improve cardiac function, protect heart tissue from damage during reduced blood flow, and enhance coronary blood flow. These effects may be independent of its growth hormone releasing properties, making it unique among GHRPs.
Muscle Growth and Strength
Higher growth hormone and IGF-1 levels support muscle protein synthesis and cellular repair. Users report improved ability to build lean mass, increased strength, and better muscle fullness. These effects develop over weeks to months of consistent use combined with proper training and adequate protein intake.
Fat Loss
Growth hormone promotes lipolysis, the breakdown of stored fat for energy. Hexarelin users commonly report reductions in body fat, particularly around the midsection. The elevated IGF-1 from growth hormone conversion in the liver also supports fat metabolism and improved body composition over time.
Improved Recovery
Growth hormone accelerates tissue repair at the cellular level. This translates to faster recovery between training sessions, reduced muscle soreness, and improved healing from minor injuries. The potent growth hormone pulses from Hexarelin provide a strong signal for your body's repair processes.
Better Sleep
Many users report improved sleep quality when using Hexarelin, particularly when dosed before bed. Growth hormone naturally peaks during deep sleep, and Hexarelin may enhance this process to produce deeper, more restorative rest.
Bone Health
IGF-1 stimulates osteoblast activity, the cells responsible for building new bone tissue. Long-term growth hormone optimization supports bone mineral density and overall skeletal health, which is particularly important for maintaining bone strength as you age.
What the Research Shows
Imbimbo and colleagues published a double-blind, placebo-controlled, rising-dose study in the European Journal of Clinical Pharmacology in 1994 evaluating Hexarelin's growth hormone releasing activity in humans. Hexarelin stimulated dose-dependent growth hormone release, subcutaneous administration was effective, it was well tolerated across tested dose ranges, and the growth hormone response was reproducible. Deghenghi and colleagues published a companion study in Life Sciences showing Hexarelin produced long-lasting growth hormone release in both infant and adult rats, slightly more effective than GHRP-6.
Research from Bhogal and colleagues published in Circulation Research in 1999 identified a new class of Hexarelin receptors in heart tissue. Studies in isolated rat hearts showed Hexarelin increased coronary perfusion pressure in a dose-dependent manner through L-type calcium channels and protein kinase C pathways. Additional cardiac research demonstrated protection against damage from reduced blood flow in aging hearts, improved left ventricular function, enhanced cardiac contractility, and effects that occurred independently of the GH/IGF-1 axis.
Arvat and colleagues published a comparative study in Peptides in 1997 examining the effects of GHRP-2 and Hexarelin on growth hormone, prolactin, ACTH, and cortisol in humans. Both peptides released growth hormone effectively, but both also caused some increase in ACTH, cortisol, and prolactin, unlike the more selective Ipamorelin. A desensitization study found minimal difference in growth hormone response between 1 week and 4 weeks of treatment, but after 16 weeks of continuous use, growth hormone release was considerably blunted. Importantly, 4 weeks after discontinuation, desensitization was completely reversed.
What to Know
Injection site redness or irritation, water retention, tingling or numbness in the hands, increased appetite, head rush or flushing after injection, and lethargy especially during the initial period of use are the most commonly reported side effects.
Unlike the more selective Ipamorelin, Hexarelin causes mild increases in cortisol and prolactin which are dose-dependent. Cortisol elevation can cause anxiety, irritability, or sleep issues at higher doses. Prolactin elevation can affect libido in some individuals. Hexarelin desensitizes receptors faster than other GHRPs. After 16 or more weeks of continuous use, growth hormone response becomes significantly blunted, though this reverses fully with 4 or more weeks off.
Do not use if you have active cancer or history of cancer, diabetic retinopathy, or are pregnant or breastfeeding. Use caution with diabetes, cardiovascular disease (though research suggests potential benefits, consult a physician), history of carpal tunnel syndrome, or anxiety disorders due to potential cortisol effects. Joint stiffness and carpal tunnel symptoms are rare but may occur at very high doses.
Research References
Growth hormone-releasing activity of hexarelin in humans: a dose-response study
Imbimbo BP, et al. · European Journal of Clinical Pharmacology · 1994
Double-blind, placebo-controlled, rising-dose study demonstrating that Hexarelin stimulates dose-dependent, reproducible growth hormone release in humans via subcutaneous administration and is well tolerated.
View StudyGH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats
Deghenghi R, et al. · Life Sciences · 1994
Demonstrated that subcutaneous Hexarelin produced long-lasting growth hormone release in both infant and adult rats, slightly more effective than GHRP-6, and described it as a highly effective growth hormone releaser.
View StudyIdentification and characterization of a new growth hormone-releasing peptide receptor in the heart
Bhogal R, et al. · Circulation Research · 1999
Identified a novel class of Hexarelin receptors in cardiovascular tissue with highest concentrations in the heart ventricles. Demonstrated dose-dependent increases in coronary perfusion pressure through L-type calcium channels and protein kinase C pathways.
View StudyEffects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man
Arvat E, et al. · Peptides · 1997
Comparative study in humans showing both GHRP-2 and Hexarelin effectively release growth hormone but also cause dose-dependent increases in ACTH, cortisol, and prolactin, unlike the more selective Ipamorelin.
View Study